Kiran Nistala Buys 3,195 Shares of Zura Bio Limited (NASDAQ:ZURA) Stock

Zura Bio Limited (NASDAQ:ZURA) EVP Kiran Nistala purchased 3,195 shares of Zura Bio stock in a transaction dated Monday, April 22nd. The shares were purchased at an average cost of $3.13 per share, with a total value of $10,000.35. Following the acquisition, the executive vice president now owns 3,195 shares of the company’s stock, valued at approximately $10,000.35. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Zura Bio Trading Down 4.9 %

Shares of ZURA stock opened at $3.31 on Thursday. Zura Bio Limited has a 1 year low of $2.00 and a 1 year high of $14.00. The stock has a fifty day moving average of $3.21 and a two-hundred day moving average of $4.04.

Analyst Ratings Changes

Separately, Oppenheimer reiterated an “outperform” rating and issued a $16.00 price objective (down from $17.00) on shares of Zura Bio in a research report on Monday, April 1st. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Zura Bio currently has a consensus rating of “Buy” and an average price target of $16.40.

Institutional Investors Weigh In On Zura Bio

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Lynx1 Capital Management LP bought a new position in Zura Bio in the 3rd quarter valued at about $65,000. Forefront Analytics LLC acquired a new stake in shares of Zura Bio in the 3rd quarter worth approximately $95,000. Bank of New York Mellon Corp bought a new position in shares of Zura Bio in the third quarter valued at approximately $224,000. Raymond James & Associates increased its stake in shares of Zura Bio by 14.0% during the third quarter. Raymond James & Associates now owns 77,356 shares of the company’s stock valued at $511,000 after acquiring an additional 9,481 shares during the period. Finally, Eisler Capital US LLC bought a new stake in Zura Bio during the third quarter worth approximately $660,000. 61.14% of the stock is currently owned by institutional investors.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.